PRNewsWire
28 Feb 2026, 12:05 UTC · 28w ago
Verdict
Headline takes no side. We score RZLT −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Rezolute's Phase 3 sunRIZE clinical trial for its lead drug candidate ersodetug failed to meet both its primary and key secondary endpoints.
So whatThe failure of a lead drug candidate in Phase 3 trials typically eliminates the primary growth catalyst for a biotech company and severely impairs its valuation.
More negative than 99% of claims this week
Rezolute's stock price collapsed approximately 85-90% on December 11, 2025, falling from near $10.94 to an intraday low of $0.90.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 98% of claims this week
Law firm Faruqi & Faruqi, LLP is investigating potential legal claims on behalf of investors who suffered losses in Rezolute stock.
More negative than 73% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company's lead drug candidate failed Phase 3 endpoints, causing a massive stock price collapse and sparking a securities investigation.
More negative than 79% of ticker scores this week
The company is mentioned in the context of a securities class action lawsuit deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
15h ago
+24.0%
Price is moving against the score
$3.98 vs $3.21 close before publication (Feb 27) · not market-adjusted
RZLT chart →
